Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares

Chief Commercial Officer Tobin W. Juvenal of Castle Biosciences Inc. recently disposed of 1,730 shares of the company's common stock, amounting to a total sale value of $51,190. This transaction took place on August 17, 2026, and was conducted within the confines of a Rule 10b5-1 trading plan, which Juvenal had established on December 10, 2025.

The shares were sold at a price fluctuating between $29.21 and $30.01, with an average sale price of $29.59 per share. Post-transaction, Juvenal remains a beneficial owner of 75,964 shares of Castle Biosciences common stock. As of the latest trading, the stock is priced at $33.42, marking a 44% increase over the past year, although analysis indicates it may be overvalued at present.

Despite the company not being profitable in the last twelve months, Castle Biosciences has demonstrated robust performance in recent months. BTIG recently upped its price target for the stock to $44, maintaining a Buy rating, after the company reported stronger-than-expected second-quarter results, surpassing analysts' estimates for both profit and revenue.